查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971161

阿兹海默症市场分析及预测（至2035年）：按类型、产品类型、服务、技术、应用、最终用户、设备、采用类型和阶段划分

Alzheimers Disease Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Device, Deployment, Stage
出版日期: | 出版商: Global Insight Services | 英文 356 Pages | 商品交期: 3-5个工作天内

价格
简介目录

阿兹海默症市场预计将从2024年的30亿美元成长到2034年的234亿美元，复合年增长率约为23%。阿兹海默症市场涵盖用于治疗和潜在治疗阿兹海默症的治疗和诊断药物的研发、生产和分销。全球人口老化和神经退化性疾病盛行率的上升是推动该市场成长的主要因素。创新重点在于缓解疾病疗法、早期检测方法和个人化医疗。监管方面的进展和合作对于加速产品开发和市场扩张至关重要。

阿兹海默症市场正经历蓬勃发展，这主要得益于诊断技术和治疗性介入的进步。治疗药物领域主导市场，其中缓解疾病药物表现尤为强劲，反映出在延缓疾病进展方面取得了显着进展。胆碱酯酶抑制剂和NMDA受体拮抗剂等对症治疗药物紧随其后，有效缓解了认知和行为症状。诊断也是一个关键领域，在生物标记检测和影像技术的推动下呈现强劲成长。生物标记相关细分领域，特别是淀粉样蛋白和Tau蛋白检测，成长速度最快，有助于提高早期检测和后续观察。包括PET和MRI扫描在内的影像技术能够提供疾病病理的详细信息，是成长第二快的领域。此外，利用人工智慧和机器学习进行预测分析和个人化医疗的数位健康解决方案也正在成为一个极具潜力的细分领域。远端医疗和远距监测工具的整合也正在加速发展，有助于实现对患者的持续管理和互动。总而言之，这些进步为阿兹海默症市场的相关人员带来了盈利的机会。

市场区隔
类型 早发性阿兹海默症、老年阿兹海默症、遗传性阿兹海默症
产品 胆碱酯酶抑制剂、NMDA受体拮抗剂、复方药物、神经保护剂、生物製药
服务 住院治疗、门诊治疗、家庭医疗保健服务、咨询服务、復健服务
科技 生物标记技术、诊断影像技术、基因组技术、数位健康技术、穿戴式技术
适用的 诊断、治疗、监测和监视
最终用户 医院、诊所、研究机构、居家医疗机构、学术机构
装置 诊断、监测、治疗和辅助设备
实施表格 基于云端、本地部署和混合的解决方案
步 临床前期、轻度认知障碍期、轻度老年痴呆症失智症期、中度老年痴呆症失智症期、重度老年痴呆症失智症期

市场概况：

阿兹海默症市场的特点是市场份额分布、定价策略和新产品上市都呈现动态变化。大型製药公司正透过新型疗法和诊断工具推动创新。由于专利到期和非专利处方药的上市，价格竞争仍然激烈。市场正经历以疾病修正治疗和早期诊断解决方案为重点的新产品上市热潮。这种竞争环境促进了快速发展和策略联盟的形成。从竞争标竿分析的角度来看，几家主要企业主导着市场，而新兴企业也透过创新解决方案崭露头角。监管的影响至关重要，严格的指导方针规范医药品认证过程。北美和欧洲处于监管发展的前沿，影响着全球市场策略。研发投入、临床试验结果和策略联盟等因素塑造了竞争格局。这些因素共同构成了一个复杂的市场环境，企业在其中努力实现差异化和合规性。在技​​术进步和法规结构的推动下，阿兹海默症市场持续发展演变。

主要趋势和驱动因素：

阿兹海默症市场正经历着由多个关键趋势和驱动因素带来的动态变化。首先，全球人口老化是关键驱动因素。随着阿兹海默症老龄化增加而增加，这一人口趋势导致患者群体不断扩大，从而推动了市场需求。生物技术和基因组学的进步正在加速新型治疗方法的研发。精准医疗和个人化治疗日益受到关注，有望带来更有效的干预措施。此外，製药公司不断增加的研发投入正在刺激创新并推动市场成长。公众意识和教育宣传活动也发挥关键作用。提高公众意识有助于早期诊断和干预，这对于控制疾病进展至关重要。政府和非营利组织对教育宣传活动的投入进一步推动了市场成长。此外，人工智慧诊断和远端监测等数位健康技术的整合正在革新患者管理。这些技术为早期发现和持续护理提供了新的机会，从而推动了市场的强劲扩张。

限制与挑战：

阿兹海默症市场面临许多重大限制和挑战。其中一项主要挑战是药物研发高成本，阻碍了中小企业进入市场，从而限制了市场竞争和创新。此外，阿兹海默症病理的复杂性使得有效治疗方法的研发面临重重挑战，导致临床试验失败率居高不下。同时，严格的监管障碍和核准流程也延缓了新疗法的上市。缺乏明确的诊断工具进一步加剧了治疗难度，早期检测仍然面临挑战，阻碍了及时干预，降低了治疗效果。此外，社会对阿兹海默症的认知和歧视也会阻碍早期诊断和治疗，这不仅影响患者的预后，也限制了市场成长。最后，高成本给患者和医疗系统带来了沉重的经济负担，限制了治疗的可近性和可负担性。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 早发性阿兹海默症
    • 晚发性阿兹海默症
    • 遗传性阿兹海默症
  • 市场规模及预测：依产品划分
    • 胆碱酯酶抑制剂
    • NMDA受体拮抗剂
    • 复方药物
    • 神经保护剂
    • 生物製药
  • 市场规模及预测：依服务划分
    • 住院治疗
    • 门诊治疗
    • 家庭医疗保健服务
    • 咨询服务
    • 復健服务
  • 市场规模及预测：依技术划分
    • 生物标记技术
    • 诊断影像技术
    • 基因组分析技术
    • 数位健康技术
    • 穿戴式科技
  • 市场规模及预测：依应用领域划分
    • 诊断
    • 治疗
    • 监测
    • 调查
  • 市场规模及预测：依最终用户划分
    • 医院
    • 诊所
    • 研究所
    • 居家医疗环境
    • 学术机构
  • 市场规模及预测：依设备划分
    • 诊断设备
    • 监测设备
    • 治疗设备
    • 辅助器具
  • 市场规模及预测：依发展状况
    • 基于云端的解决方案
    • 本地部署解决方案
    • 混合解决方案
  • 市场规模及预测：依发展阶段划分
    • 临床前阶段
    • 轻度认知障碍阶段
    • 轻度老年痴呆症失智症阶段
    • 中度老年痴呆症失智症阶段
    • 重度老年痴呆症失智症阶段

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • AC Immune
  • BioArctic
  • Cassava Sciences
  • Anavex Life Sciences
  • Axovant Gene Therapies
  • Alzheon
  • Cortexyme
  • Annovis Bio
  • Neurotrope
  • Cognition Therapeutics
  • Intra-Cellular Therapies
  • ProMIS Neurosciences
  • Eisai Co
  • Denali Therapeutics
  • vTv Therapeutics

第九章：关于我们

简介目录
Product Code: GIS33609

Alzheimers Disease Marketis anticipated to expand from $3.0 billion in 2024 to $23.4 billion by 2034, growing at a CAGR of approximately 23%. The Alzheimer's Disease Market encompasses the development, production, and distribution of therapeutics and diagnostics aimed at managing and potentially curing Alzheimer's. This market is driven by an aging global population and increasing prevalence of neurodegenerative disorders. Innovations focus on disease-modifying treatments, early detection methods, and personalized medicine. Regulatory advancements and collaborations are pivotal in accelerating product development and market expansion.

The Alzheimer's Disease Market is experiencing dynamic growth, propelled by advancements in diagnostics and therapeutic interventions. The therapeutics segment dominates, with disease-modifying treatments leading performance, reflecting significant strides in slowing disease progression. Symptomatic treatments, such as cholinesterase inhibitors and NMDA receptor antagonists, follow closely, addressing cognitive and behavioral symptoms effectively. Diagnostics, another critical segment, is witnessing robust growth, driven by biomarker-based assays and imaging technologies. Biomarkers, particularly amyloid and tau protein assays, are top-performing sub-segments, enhancing early detection and monitoring. Imaging technologies, including PET and MRI scans, are the second highest performing, offering detailed insights into disease pathology. Furthermore, digital health solutions are emerging as a promising sub-segment, leveraging AI and machine learning for predictive analytics and personalized care. The integration of telemedicine and remote monitoring tools is also gaining momentum, facilitating continuous patient management and engagement. Collectively, these advancements present lucrative opportunities for stakeholders in the Alzheimer's Disease Market.

Market Segmentation
TypeEarly-Onset Alzheimer's, Late-Onset Alzheimer's, Familial Alzheimer's
ProductCholinesterase Inhibitors, NMDA Receptor Antagonists, Combination Drugs, Neuroprotective Agents, Biologics
ServicesIn-Patient Care, Out-Patient Care, Home Healthcare Services, Counseling Services, Rehabilitation Services
TechnologyBiomarker Technology, Imaging Technology, Genomics Technology, Digital Health Technology, Wearable Technology
ApplicationDiagnosis, Treatment, Monitoring, Research
End UserHospitals, Clinics, Research Institutes, Homecare Settings, Academic Institutions
DeviceDiagnostic Devices, Monitoring Devices, Therapeutic Devices, Assistive Devices
DeploymentCloud-Based Solutions, On-Premise Solutions, Hybrid Solutions
StagePreclinical Stage, Mild Cognitive Impairment Stage, Mild Alzheimer's Dementia Stage, Moderate Alzheimer's Dementia Stage, Severe Alzheimer's Dementia Stage

Market Snapshot:

The Alzheimer's Disease market is characterized by a dynamic landscape of market share distribution, pricing strategies, and new product launches. Leading pharmaceutical companies are driving innovation with novel therapeutics and diagnostic tools. Pricing remains competitive, influenced by patent expirations and generic drug entries. The market is witnessing a surge in new product launches, focusing on disease-modifying therapies and early diagnosis solutions. This competitive environment fosters an atmosphere of rapid development and strategic partnerships. In terms of competition benchmarking, several key players dominate the market, with emerging companies gaining traction through innovative solutions. Regulatory influences play a critical role, with stringent guidelines governing drug approval processes. North America and Europe are at the forefront of regulatory advancements, impacting global market strategies. The competitive landscape is shaped by factors such as R&D investments, clinical trial outcomes, and strategic alliances. These elements contribute to a complex market environment, where companies strive to achieve differentiation and regulatory compliance. The Alzheimer's Disease market continues to evolve, driven by technological advancements and regulatory frameworks.

Geographical Overview:

The Alzheimer's Disease market is witnessing substantial growth across various regions, each with unique characteristics. North America leads with robust research initiatives and significant investments in innovative therapies. The presence of major pharmaceutical companies enhances the region's market position, fostering the development of novel treatments. Europe follows, driven by strong healthcare infrastructure and government support for Alzheimer's research. The region's focus on early diagnosis and intervention further propels market expansion. In the Asia Pacific, the market is expanding rapidly due to increasing awareness and a growing elderly population. Countries like China and Japan are emerging as key players, investing heavily in research and development. Latin America and the Middle East & Africa present new growth pockets, with rising healthcare investments and improved access to treatment options. Countries such as Brazil and the UAE are recognizing the importance of addressing Alzheimer's Disease, leading to increased market potential. These regions offer lucrative opportunities for stakeholders aiming to expand their presence in the Alzheimer's Disease market.

Key Trends and Drivers:

The Alzheimer's Disease market is experiencing dynamic shifts driven by several key trends and drivers. Firstly, the aging global population is a significant driver, as the prevalence of Alzheimer's increases with age. This demographic trend is creating an expanding patient pool, thereby boosting market demand. Advancements in biotechnology and genomics are accelerating the development of novel therapeutic approaches. Precision medicine and personalized treatments are gaining traction, offering potential for more effective interventions. Furthermore, increased investment in research and development by pharmaceutical companies is fostering innovation and driving market growth. Public awareness and advocacy efforts are also playing a crucial role. Increased awareness is leading to earlier diagnosis and intervention, which is vital for managing the disease's progression. Governments and non-profit organizations are investing in educational campaigns, further enhancing market growth. Additionally, the integration of digital health technologies, such as AI-driven diagnostics and remote monitoring, is revolutionizing patient management. These technologies offer new opportunities for early detection and continuous care, positioning the market for robust expansion.

Restraints and Challenges:

The Alzheimer's Disease market encounters several significant restraints and challenges. A primary challenge is the high cost of drug development, which impedes smaller companies from entering the market. This results in limited competition and innovation. Furthermore, the complex nature of Alzheimer's Disease pathology complicates the development of effective treatments, leading to high failure rates in clinical trials. Additionally, regulatory hurdles are substantial, with stringent approval processes delaying market entry for new therapies. The lack of definitive diagnostic tools further complicates treatment, as early detection remains elusive. This impedes timely intervention, reducing treatment efficacy. Moreover, public perception and stigma surrounding Alzheimer's Disease can deter patients from seeking early diagnosis and treatment. This not only affects patient outcomes but also limits market growth. Finally, the high cost of care and treatment poses a financial burden on patients and healthcare systems, restricting access and affordability.

Key Players:

AC Immune, BioArctic, Cassava Sciences, Anavex Life Sciences, Axovant Gene Therapies, Alzheon, Cortexyme, Annovis Bio, Neurotrope, Cognition Therapeutics, Intra-Cellular Therapies, ProMIS Neurosciences, Eisai Co, Denali Therapeutics, vTv Therapeutics

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Device
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Early-Onset Alzheimer's
    • 4.1.2 Late-Onset Alzheimer's
    • 4.1.3 Familial Alzheimer's
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Cholinesterase Inhibitors
    • 4.2.2 NMDA Receptor Antagonists
    • 4.2.3 Combination Drugs
    • 4.2.4 Neuroprotective Agents
    • 4.2.5 Biologics
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 In-Patient Care
    • 4.3.2 Out-Patient Care
    • 4.3.3 Home Healthcare Services
    • 4.3.4 Counseling Services
    • 4.3.5 Rehabilitation Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Biomarker Technology
    • 4.4.2 Imaging Technology
    • 4.4.3 Genomics Technology
    • 4.4.4 Digital Health Technology
    • 4.4.5 Wearable Technology
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Diagnosis
    • 4.5.2 Treatment
    • 4.5.3 Monitoring
    • 4.5.4 Research
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Clinics
    • 4.6.3 Research Institutes
    • 4.6.4 Homecare Settings
    • 4.6.5 Academic Institutions
  • 4.7 Market Size & Forecast by Device (2020-2035)
    • 4.7.1 Diagnostic Devices
    • 4.7.2 Monitoring Devices
    • 4.7.3 Therapeutic Devices
    • 4.7.4 Assistive Devices
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 Cloud-Based Solutions
    • 4.8.2 On-Premise Solutions
    • 4.8.3 Hybrid Solutions
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Preclinical Stage
    • 4.9.2 Mild Cognitive Impairment Stage
    • 4.9.3 Mild Alzheimer's Dementia Stage
    • 4.9.4 Moderate Alzheimer's Dementia Stage
    • 4.9.5 Severe Alzheimer's Dementia Stage

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Device
      • 5.2.1.8 Deployment
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Device
      • 5.2.2.8 Deployment
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Device
      • 5.2.3.8 Deployment
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Device
      • 5.3.1.8 Deployment
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Device
      • 5.3.2.8 Deployment
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Device
      • 5.3.3.8 Deployment
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Device
      • 5.4.1.8 Deployment
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Device
      • 5.4.2.8 Deployment
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Device
      • 5.4.3.8 Deployment
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Device
      • 5.4.4.8 Deployment
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Device
      • 5.4.5.8 Deployment
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Device
      • 5.4.6.8 Deployment
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Device
      • 5.4.7.8 Deployment
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Device
      • 5.5.1.8 Deployment
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Device
      • 5.5.2.8 Deployment
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Device
      • 5.5.3.8 Deployment
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Device
      • 5.5.4.8 Deployment
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Device
      • 5.5.5.8 Deployment
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Device
      • 5.5.6.8 Deployment
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Device
      • 5.6.1.8 Deployment
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Device
      • 5.6.2.8 Deployment
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Device
      • 5.6.3.8 Deployment
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Device
      • 5.6.4.8 Deployment
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Device
      • 5.6.5.8 Deployment
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 AC Immune
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 BioArctic
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Cassava Sciences
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Anavex Life Sciences
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Axovant Gene Therapies
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Alzheon
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Cortexyme
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Annovis Bio
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Neurotrope
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Cognition Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Intra-Cellular Therapies
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 ProMIS Neurosciences
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Eisai Co
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Denali Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 vTv Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us